Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.

Show other versions (1)

Bibliographic Details
Main Authors:	Kitley, J, Leite, M, Elsone, L, Jacob, A, Palace, J
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2014

Similar Items

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
by: Kitley, J, et al.
Published: (2014)

Seasonal pattern of variation in neuromyelitis optica relapses
by: Elsone, L, et al.
Published: (2012)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
by: Kitley, J, et al.
Published: (2012)

Use of mitoxantrone in neuromyelitis optica.
by: Kitley, J, et al.
Published: (2011)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
by: Elsone, L, et al.
Published: (2012)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

A clinical/immunological neuromyelitis optica association study
by: Kitley, J, et al.
Published: (2014)

Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.
by: Jacob, A, et al.
Published: (2012)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
by: Luppe, S, et al.
Published: (2012)

Is azathioprine effective in highly-active neuromyelitis optica? A multicentre study from the United Kingdom
by: Elsone, L, et al.
Published: (2013)

Prognosis of Relapsing Neuromyelitis Optica
by: J Gordon Millichap
Published: (2003-03-01)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
by: Tackley, G, et al.
Published: (2016)

A practical guide to the treatment of neuromyelitis optica.
by: Palace, J, et al.
Published: (2012)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
by: Absoud, M, et al.
Published: (2014)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
by: Kitley, J, et al.
Published: (2013)

LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS: A VARIETY OF CAUSES SEEN WITHIN THE NATIONAL NEUROMYELITIS OPTICA SERVICE
by: Kitley, J, et al.
Published: (2012)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
by: Sedani, S, et al.
Published: (2012)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
by: Palace, J, et al.
Published: (2010)

Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort
by: Leonard, H, et al.
Published: (2012)

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
by: Kitley, J, et al.
Published: (2012)

The borderland of neuromyelitis optica.
by: Matthews, L, et al.
Published: (2009)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
by: George, J, et al.
Published: (2012)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
by: Waters, P, et al.
Published: (2015)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
by: Kitley, J, et al.
Published: (2014)

The evolving clinical spectrum of neuromyelitis optica
by: Viegas, S, et al.
Published: (2008)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

Relapsing neuromyelitis optica spectrum disorder
by: M Lakshmi Lavanya, et al.
Published: (2021-01-01)

Long term efficacy, adherence and reasons for discontinuation in 103 cases of neuromyelitis optica treated with azathioprine: a multicentre study from the United Kingdom
by: Elsone, L, et al.
Published: (2013)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

Magnetic resonance imaging in neuromyelitis optica.
by: Tackley, G, et al.
Published: (2014)

Myelin-oligodendrocyte glycoprotein antibody-mediated acute inflammatory demyelinating disease mimicking neuromyelitis optica
by: Kitley, J, et al.
Published: (2011)

Neuromyelitis optica
by: Jacob Anu, et al.
Published: (2007-01-01)

Treatment of Neuromyelitis Optica: Review and Recommendations.
by: Kimbrough, D, et al.
Published: (2012)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
by: Fujihara, K, et al.
Published: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2013)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
by: Kitley, J, et al.
Published: (2012)